Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $8,017 | 425 | 97.0% |
| Education | $243.77 | 38 | 3.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $1,466 | 54 | $0 (2021) |
| E.R. Squibb & Sons, L.L.C. | $934.37 | 52 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $763.60 | 39 | $0 (2020) |
| Janssen Pharmaceuticals, Inc | $749.70 | 53 | $0 (2020) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $684.86 | 61 | $0 (2020) |
| PFIZER INC. | $659.57 | 64 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $625.66 | 39 | $0 (2020) |
| AstraZeneca Pharmaceuticals LP | $525.14 | 33 | $0 (2020) |
| Regeneron Healthcare Solutions, Inc. | $298.62 | 19 | $0 (2019) |
| Ablacon, Inc. | $241.24 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $25.00 | 1 | E.R. Squibb & Sons, L.L.C. ($25.00) |
| 2023 | $241.24 | 1 | Ablacon, Inc. ($241.24) |
| 2021 | $11.72 | 1 | Amgen Inc. ($11.72) |
| 2020 | $731.11 | 29 | Medicure Pharma Inc. ($227.81) |
| 2019 | $2,612 | 156 | Amgen Inc. ($586.95) |
| 2018 | $2,093 | 125 | Amgen Inc. ($466.37) |
| 2017 | $2,546 | 150 | Amgen Inc. ($381.79) |
All Payment Transactions
463 individual payment records from CMS Open Payments — Page 3 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/20/2019 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $21.90 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/15/2019 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $15.56 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 11/14/2019 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $21.16 | General |
| Category: Cardiology | ||||||
| 11/07/2019 | SANOFI-AVENTIS U.S. LLC | PRALUENT (Drug) | Food and Beverage | In-kind items and services | $20.92 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/06/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | PRADAXA (Drug) | Education | In-kind items and services | $7.08 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/06/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Education | In-kind items and services | $7.08 | General |
| Category: DIABETES | ||||||
| 11/01/2019 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $17.80 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 10/31/2019 | Regeneron Healthcare Solutions, Inc. | PRALUENT (Biological) | Food and Beverage | In-kind items and services | $32.85 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 10/31/2019 | Regeneron Healthcare Solutions, Inc. | PRALUENT (Biological) | Food and Beverage | In-kind items and services | $1.28 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 10/30/2019 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $23.45 | General |
| Category: Cardiovascular | ||||||
| 10/30/2019 | Novartis Pharmaceuticals Corporation | ENTRESTO (Drug) | Food and Beverage | In-kind items and services | $22.73 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/18/2019 | Janssen Pharmaceuticals, Inc | XARELTO (Drug) | Food and Beverage | In-kind items and services | $23.05 | General |
| Category: Cardiovascular & Metabolism | ||||||
| 10/17/2019 | SANOFI-AVENTIS U.S. LLC | MULTAQ (Drug) | Food and Beverage | In-kind items and services | $18.65 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/16/2019 | Amgen Inc. | Repatha (Biological) | Food and Beverage | In-kind items and services | $31.54 | General |
| Category: Cardiology | ||||||
| 10/16/2019 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $18.38 | General |
| Category: Anemia | ||||||
| 10/15/2019 | Regeneron Healthcare Solutions, Inc. | PRALUENT (Biological) | Food and Beverage | In-kind items and services | $16.00 | General |
| Category: CARDIOVASCULAR AND METABOLISM | ||||||
| 10/15/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | PRADAXA (Drug) | Education | In-kind items and services | $7.08 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/15/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Education | In-kind items and services | $7.08 | General |
| Category: DIABETES | ||||||
| 10/10/2019 | E.R. Squibb & Sons, L.L.C. | ELIQUIS (Drug) | Food and Beverage | Cash or cash equivalent | $21.87 | General |
| Category: Cardiovascular | ||||||
| 10/10/2019 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $16.23 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/09/2019 | PFIZER INC. | VYNDAQEL (Drug) | Education | In-kind items and services | $7.90 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/09/2019 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $2.14 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/09/2019 | PFIZER INC. | VYNDAQEL (Drug) | Food and Beverage | In-kind items and services | $0.47 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/04/2019 | SANOFI-AVENTIS U.S. LLC | MULTAQ (Drug) | Food and Beverage | In-kind items and services | $18.46 | General |
| Category: CARDIOVASCULAR | ||||||
| 10/02/2019 | Boehringer Ingelheim Pharmaceuticals, Inc. | PRADAXA (Drug), JARDIANCE | Food and Beverage | In-kind items and services | $22.95 | General |
| Category: CARDIOVASCULAR | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 27 | 4,030 | 5,706 | $3.4M | $822,294 |
| 2022 | 32 | 3,987 | 5,730 | $3.1M | $784,403 |
| 2021 | 34 | 3,893 | 5,745 | $3.2M | $839,534 |
| 2020 | 30 | 3,604 | 5,765 | $2.8M | $709,301 |
All Medicare Procedures & Services
126 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 943 | 1,595 | $779,955 | $252,224 | 32.3% |
| 78492 | Nuclear medicine studies of blood flow in heart muscle at rest and with stress | Office | 2023 | 108 | 108 | $978,372 | $166,454 | 17.0% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Office | 2023 | 677 | 698 | $614,057 | $133,757 | 21.8% |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | Office | 2023 | 108 | 216 | $186,840 | $90,159 | 48.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 187 | 187 | $130,339 | $37,854 | 29.0% |
| 93351 | Ultrasound of heart with continuous electrocardiogram (ecg) during rest, exercise and/or drug induced stress with review and report | Office | 2023 | 162 | 163 | $176,366 | $37,699 | 21.4% |
| J2785 | Injection, regadenoson, 0.1 mg | Office | 2023 | 111 | 444 | $66,600 | $18,723 | 28.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 73 | 143 | $52,195 | $15,360 | 29.4% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 637 | 982 | $81,506 | $12,404 | 15.2% |
| 93280 | Programming of dual lead pacemaker system | Office | 2023 | 69 | 128 | $38,912 | $9,982 | 25.7% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 44 | 49 | $34,496 | $7,268 | 21.1% |
| 76376 | 3d radiographic procedure | Office | 2023 | 222 | 232 | $78,184 | $5,744 | 7.3% |
| 93970 | Ultrasound study of arm or leg veins with compression and maneuvers | Office | 2023 | 27 | 29 | $30,073 | $5,466 | 18.2% |
| 93015 | Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | Office | 2023 | 75 | 75 | $26,325 | $5,135 | 19.5% |
| 93458 | Insertion of tube in left lower heart chamber and coronary artery for diagnosis with review by radiologist | Facility | 2023 | 18 | 18 | $13,050 | $3,612 | 27.7% |
| 93290 | Evaluation of implantable heart and blood vessel monitoring system | Office | 2023 | 32 | 64 | $8,448 | $3,004 | 35.6% |
| 93281 | Programming of multiple lead pacemaker system | Office | 2023 | 20 | 36 | $12,708 | $2,925 | 23.0% |
| 93244 | Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 123 | 128 | $11,648 | $2,642 | 22.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 24 | 24 | $8,736 | $1,955 | 22.4% |
| 93356 | Heart muscle strain imaging | Office | 2023 | 45 | 47 | $8,789 | $1,835 | 20.9% |
| 93242 | Heart rhythm recording continous external ekg over more than 48 hours up to 7 days | Office | 2023 | 124 | 129 | $7,998 | $1,548 | 19.4% |
| 93248 | Heart rhythm review and interpretation of continous external ekg over 8-15 days | Office | 2023 | 60 | 63 | $6,363 | $1,452 | 22.8% |
| 92960 | External shock to heart to regulate heart beat | Facility | 2023 | 14 | 14 | $13,818 | $1,386 | 10.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 15 | 19 | $4,693 | $1,349 | 28.7% |
| 93306 | Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | Facility | 2023 | 16 | 16 | $3,968 | $987.09 | 24.9% |
About Dr. Bruce Benedick, M.D
Dr. Bruce Benedick, M.D is a Interventional Cardiology healthcare provider based in E Palo Alto, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/10/2006. The National Provider Identifier (NPI) number assigned to this provider is 1346274602.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Bruce Benedick, M.D has received a total of $8,260 in payments from pharmaceutical and medical device companies, with $25.00 received in 2024. These payments were reported across 463 transactions from 32 companies. The most common payment nature is "Food and Beverage" ($8,017).
As a Medicare-enrolled provider, Benedick has provided services to 15,514 Medicare beneficiaries, totaling 22,946 services with total Medicare billing of $3.2M. Data is available for 4 years (2020–2023), covering 126 distinct procedure/service records.
Practice Information
- Specialty Interventional Cardiology
- Other Specialties Nuclear Cardiology, Cardiovascular Disease
- Location E Palo Alto, CA
- Active Since 07/10/2006
- Last Updated 05/28/2020
- Taxonomy Code 207RI0011X
- Entity Type Individual
- NPI Number 1346274602
Products in Payments
- ELIQUIS (Drug) $1,451
- Corlanor (Drug) $848.72
- XARELTO (Drug) $732.75
- ENTRESTO (Drug) $625.66
- Repatha (Biological) $617.42
- PRALUENT (Drug) $580.21
- BRILINTA (Drug) $525.14
- PRADAXA (Drug) $508.21
- Heart Failure Device. (Device) $227.81
- MULTAQ (Drug) $183.39
- JARDIANCE (Drug) $176.65
- PRALUENT (Biological) $160.72
- PRALUENT ALIROCUMAB INJECTION (Biological) $137.90
- VYNDAQEL (Drug) $122.12
- KENGREAL (Drug) $117.44
- Circulatory Support (Device) $106.27
- WATCHMAN (Device) $99.45
- LifeVest (Device) $74.09
- Veltassa (Drug) $58.45
- Vascepa (Drug) $56.57
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.